{"id":"atg-fresenius","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Serum sickness"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL4482864","moleculeType":"Small molecule","molecularWeight":"494.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG Fresenius is derived from rabbit serum immunized against human thymocytes. It contains polyclonal antibodies that recognize multiple epitopes on T cells, leading to T-cell depletion through complement activation and opsonization. This immunosuppressive effect is used to prevent graft rejection and treat aplastic anemia by reducing the T-cell mediated immune response.","oneSentence":"ATG Fresenius is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:21.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute rejection in renal transplantation"},{"name":"Treatment of aplastic anemia"},{"name":"Prevention of graft-versus-host disease in hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT02392312","phase":"","title":"Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2015-01-21","conditions":"Kidney Transplant Recipients","enrollment":950},{"nctId":"NCT03357159","phase":"PHASE2","title":"Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2018-09-06","conditions":"Graft Versus Host Disease","enrollment":30},{"nctId":"NCT01582048","phase":"PHASE2","title":"Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","status":"TERMINATED","sponsor":"Prof. Dr. med. Wolfgang Bethge","startDate":"2012-04","conditions":"Patients Receiving Mismatched Allogeneic HCT","enrollment":9},{"nctId":"NCT00886522","phase":"PHASE2","title":"Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2009-04","conditions":"Hematological Malignancies","enrollment":23},{"nctId":"NCT02523768","phase":"PHASE4","title":"Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2011-01-08","conditions":"Glomerulonephritis, IgAN","enrollment":117},{"nctId":"NCT03963024","phase":"PHASE1","title":"Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT","status":"TERMINATED","sponsor":"IRCCS San Raffaele","startDate":"2014-02-12","conditions":"Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy, Leukemia, Acute","enrollment":9},{"nctId":"NCT03631563","phase":"PHASE2, PHASE3","title":"ATG-F VS ATG for the Prevention of GVHD","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2013-03-01","conditions":"GVHD in the Setting of Haplo-HSCT","enrollment":120},{"nctId":"NCT02843841","phase":"NA","title":"Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2014-12","conditions":"Disorder Related to Renal Transplantation","enrollment":63},{"nctId":"NCT02028416","phase":"NA","title":"Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia","status":"UNKNOWN","sponsor":"National Institute of Blood Disease Center, Pakistan","startDate":"2013-09","conditions":"Aplastic Anemia","enrollment":60},{"nctId":"NCT01423747","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2003-07","conditions":"Lymphoblastic Leukemia, Acute, Childhood;","enrollment":400},{"nctId":"NCT01423500","phase":"PHASE3","title":"ALL-SCT BFM International- HSCT in Children and Adolescents With ALL","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2007-01","conditions":"Lymphoblastic Leukemia, Acute, Childhood;","enrollment":405},{"nctId":"NCT02478424","phase":"PHASE2","title":"Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2015-07","conditions":"Graft vs Host Disease","enrollment":10},{"nctId":"NCT00678275","phase":"PHASE3","title":"Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2006-10","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":161},{"nctId":"NCT00682305","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2007-03","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT01324934","phase":"PHASE3","title":"Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids","status":"TERMINATED","sponsor":"Neovii Biotech","startDate":"2006-10","conditions":"Renal Transplant Rejection","enrollment":40},{"nctId":"NCT00616954","phase":"PHASE3","title":"A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT","status":"TERMINATED","sponsor":"Hadassah Medical Organization","startDate":"2008-05","conditions":"Allogeneic Haplo-Stem Cell Transplatation (SCT), Graft Versus Host Disease","enrollment":50},{"nctId":"NCT00861536","phase":"PHASE4","title":"Comparison of ATG to Thymoglobuline in Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-01","conditions":"Transplantation, Kidney","enrollment":40},{"nctId":"NCT01810926","phase":"PHASE2","title":"T&B Depletion Non Malignant","status":"UNKNOWN","sponsor":"Franco Locatelli","startDate":"2011-09","conditions":"Graft Versus Host Disease","enrollment":130},{"nctId":"NCT00316810","phase":"PHASE3","title":"Simultaneous Pancreas-kidney Transplantation With Campath Protocol","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2006-04","conditions":"Pancreas-Kidney Transplantation","enrollment":30},{"nctId":"NCT00655343","phase":"PHASE3","title":"Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)","status":"COMPLETED","sponsor":"Neovii Biotech","startDate":"2003-02","conditions":"Graft vs Host Disease","enrollment":202},{"nctId":"NCT00934557","phase":"PHASE3","title":"Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2008-03","conditions":"Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer","enrollment":42},{"nctId":"NCT00436722","phase":"PHASE2","title":"Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial","status":"TERMINATED","sponsor":"Hospital Clinic of Barcelona","startDate":"2006-06","conditions":"Liver Diseases","enrollment":72},{"nctId":"NCT00742300","phase":"PHASE1, PHASE2","title":"Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"1998-01","conditions":"Autoimmune Diseases","enrollment":""},{"nctId":"NCT00733733","phase":"PHASE3","title":"Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2008-01","conditions":"Renal Transplant Patients, Recipients of a Kidney From a Non-Heart-Beating Donor","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":132,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Simulect IV 40 mg/day D0 and D4","and oral use Tacrolimus 0.1 mg/ kg/ day +","Myfortic 720 to 1440mg +","Corticosteroids 5mg"],"phase":"marketed","status":"active","brandName":"ATG Fresenius","genericName":"ATG Fresenius","companyName":"University Hospital, Basel, Switzerland","companyId":"university-hospital-basel-switzerland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATG Fresenius is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity. Used for Prevention of acute organ rejection in allogeneic transplantation, Treatment of aplastic anemia, Treatment of acute graft-versus-host disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}